Hyperconjugated side chained benzodithiophene and 4,7-di-2-thienyl-2,1,3-benzothiadiazole based polymer for solar cells

A novel donor-acceptor (D-A) copolymer (P3TBDTDTBT), including hyperconjugated side chained benzodithiophene as a donor and 4,7-di-2-thienyl-2,1,3-benzothiadiazole (DTBT) as an acceptor, was designed and synthesized. Due to the introduction of the hyperconjugated side chain, the resultant polymer exhibited good thermal stability with a high decomposition temperature of 437 degrees C, a low band-gap of 1.67 eV with an absorption onset of 742 nm in the solid film, and a deep highest occupied molecular orbital (HOMO) energy level of -5.26 eV. Finally, the polymer solar cell (PSC) device based on this polymer and [6,6]-phenyl-C-61-butyric acid methyl ester (PCBM) showed the best power conversion efficiency (PCE) of 3.57% with an open-circuit voltage (V-oc) of 0.78 V, a short-circuit current density (J(sc)) of 8.83 mA cm(-2) and a fill factor (FF) of 53%

Task Space Trajectory Tracking Control of Robot Manipulators with Uncertain Kinematics and Dynamics

To improve the tracking precision of robot manipulators’ end-effector with uncertain kinematics and dynamics in the task space, a new control method is proposed. The controller is based on time delay estimation and combines with the nonsingular terminal sliding mode (NTSM) and adaptive fuzzy logic control scheme. Kinematic parameters are not exactly required with the consideration of kinematic uncertainties in the controller. No dynamic models or numerous parameters of the robot manipulator system are required with the use of TDE. Thus, the controller is simple structure and suitable for practical applications. Furthermore, errors caused by time delay estimation are compensated by the adaptive fuzzy nonsingular terminal sliding mode scheme. The simulation is performed on a 2-DOF robot manipulator with three cases in the task space. The results show that the proposed controller provides faster convergence rate and higher tracking precision than TDE based NTSM and improved TDE based NTSM controller

ATR Inhibitors in Platinum-Resistant Ovarian Cancer

Platinum-resistant ovarian cancer (PROC) is one of the deadliest types of epithelial ovarian cancer, and it is associated with a poor prognosis as the median overall survival (OS) is less than 12 months. Targeted therapy is a popular emerging treatment method. Several targeted therapies, including those using bevacizumab and poly (ADP-ribose) polymerase inhibitor (PARPi), have been used to treat PROC. Ataxia telangiectasia and RAD3-Related Protein Kinase inhibitors (ATRi) have attracted attention as a promising class of targeted drugs that can regulate the cell cycle and influence homologous recombination (HR) repair. In recent years, many preclinical and clinical studies have demonstrated the efficacy of ATRis in PROC. This review focuses on the anticancer mechanism of ATRis and the progress of research on ATRis for PROC